Progressive stroke
Conditions
Interventions
Experimental group1:Agartreban is administered intravenously
Experimental group2:Intravenous use of tirofiban
Control group:aspirin+clopidogrel
Sponsors
Nanfang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. All patients met the diagnostic criteria for cerebal infarction in the Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke 2018; 2. Progressive stroke patients whose onset was within 6h-1 week and whose NIHSS score increased by at least 1 point. 3. None of them received thrombolytic therapy; 4. First onset or previous onset without obvious sequelae; 5. The patients and their family members signed the informed consent for anticoagulation, anti-plate therapy and DSA.
Exclusion criteria
Exclusion criteria: 1, TIA; 2, cerebral hemorrhage, subarachnoid hemorrhage, hemorrhagic cerebral infarction, brain tumor; 3. Cardiogenic cerebral embolism; 4. Stroke patients with large-scale cerebral infarction or severe consciousness disturbance (NIHSS score 20 points); 5. Complicated with serious heart and lung insufficiency, abnormal liver and kidney function, and diseases of the blood system; 6. Abnormal coagulation function, thrombocytopenia or bleeding tendency, recent (3 months) active bleeding, aortic arch dissection, etc; 7. Tumor patients; 8. Advanced dementia patients; 9. Patients with allergy or allergy to agatreban, tirofiban, antiplatelet drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIHSS;mRS;complication;mortality rate;Barthel Index Rating Table; | — |
Countries
China
Contacts
Public ContactLiang Haiou
Zengcheng Branch of Nanfang Hospital
Outcome results
None listed